NOVEL THERAPIES & NEXT-GEN MEDICAL DEVICES IN CARDIOVASCULAR & VASCULAR DISEASE MANAGEMENT
With
Professor Shirley Jansen AM
The Lawrence-Brown Chair of Vascular Surgery,
School of Population Health,
Curtin University &
Head of the Department of Vascular and Endovascular Surgery,
Sir Charles Gairdner Hospital &
Director of the Heart and Vascular Research Institute,
Harry Perkins Institute of Medical Research, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | June 2026
Professor Shirley Jansen AM is a distinguished vascular and endovascular surgeon whose career spans clinical leadership, academic excellence, and pioneering research. She currently holds the Lawrence-Brown Chair of Vascular Surgery at Curtin University’s School of Population Health and serves as Head of the Department of Vascular Surgery at Sir Charles Gairdner Hospital, a role she has held since 2015. In addition, she is the Director of the Heart & Vascular Research Institute at the Harry Perkins Institute for Medical Research. Her early career was marked by prestigious fellowships, including a British Heart Foundation Research Fellowship (1996), and multiple international travelling fellowships from leading surgical societies and industry sponsors between 2001 and 2002.
Professor Jansen has over 20 years of experience treating vascular disease and has played a vital role in shaping healthcare policy, and clinical standards. She has been Site PI in over 50 clinical trials in pharma, device, first in man, RCTS and registries, many global and leading to changes in practice. She has over 150 peer-reviewed publications, including chapters in key surgical textbooks. Her research has attracted over $14 million in funding, supporting groundbreaking work in biologic therapeutics, vascular medicine, and international clinical trials.
Professor Jansen is Co-Founder and Director of Atherid Therapeutics Pty Ltd developing a novel first in class therapeutic to remove cholesterol and lipid from the arterial wall in atherosclerosis with inventor A/Prof Juliana Hamzah, Head of Targeted Drug Delivery, Imaging and Therapeutics Lab, Harry Perkins Institute of Medical Research. S Jansen’s other main research interest is in the mechanical impacts on the vessel wall as it relates to arterial disease and intervention, and the development of 3D bioprinted vascular devices with her colleague A/Prof Elena Juan Pardo, an expert in bioengineering at the Perkins.
Source: Supplied
You Might also like
-
Genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia
Prof Deborah White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
-
Dr Venkata Tarigoppula
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.